Titan Pharmaceuticals Announces Spheramine® Initial Phase IIb Results

 04.07.2008 06:14   medicalnewstoday.com

Titan Pharmaceuticals, Inc. (AMEX:TTP) announced initial analyses show that Spheramine® did not meet the Phase IIb clinical study's primary or key secondary endpoints, with no significant differences detected between the Spheramine and sham surgery arms of the study after 12 months of follow-up.

World Parkinson's Disease